Heat shock protein 90 regulates the expression of Wilms tumor 1 protein in myeloid leukemias
Hima Bansal(The University of Texas at San Antonio Health Science Center), Kevin R. Kelly(Keck Hospital of USC), Ronan Swords(University of Miami), Kevin P. Foley(Unknown), Maria R. Baer(University of Maryland, Baltimore), Kelvin P. Lee(Roswell Park Comprehensive Cancer Center), Gail E. Tomlinson(Urology San Antonio), David A. Proia(C4 Therapeutics (United States)), Manjeet K. Rao(Children's Cancer Center), Francis J. Giles(National University of Ireland), Minoo Battiwalla(Sarah Cannon), Ronald K. Blackman(Harvard University), James Barsoum(Celldex Therapeutics (United States)), Weiwen Ying(Synta Pharmaceuticals (United States)), Sanjay Bansal(King's College Hospital), Jim Sang(Synta Pharmaceuticals (United States))
Cited by 46
Related Papers
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951